Journals / Göztepe Tıp Dergisi / 2009 / Cilt: 24 - Sayı: 4

Association of different insulin treatment regimens with weight gain in patients with type 2 diabetes mellitus

Tip 2 diabetes mellituslu hastalarda farklı insulin tedavi protokollerinin kilo alımı ile ilişkisi

Pages
183–191
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Anthropometric measurements, fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) values of all patients were recorded at 3rd and 6th months.Results: In all groups, we observed statistically significant increase in both weight and body mass index (BMI) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Obesity is a factor which eases development and complicates treatment of type 2 diabetes mellitus.
📊
Key Findings & Data:Increase in central weight causes increase in adipose tissue, which leads to an increase in adipokines and free fatty acids (FFA), this inducing insulin resistance.
💡
Conclusion & Impact:Anthropometric measurements, fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) values of all patients were recorded at 3rd and 6th months.Results: In all groups, we observed statistically significant increase in both weight and body mass index (BMI) (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Obesity is a factor which eases development and complicates treatment of type 2 diabetes mellitus. Increase in central weight causes increase in adipose tissue, which leads to an increase in adipokines and free fatty acids (FFA), this inducing insulin resistance. However, weight-gain is observed in patients in whom oral antidiabetic (OAD) therapy is switched to insulin in order to maintain good glycemic control. In our study, we aimed to investigate the effect of different insulin therapies on weight.Material and Methods: 129 diabetic patients, to whom insulin therapy will be applied for the first time, were received to the study. Insulin detemir + short acting analogous insulin (aspart) group consisted of 18 patients, whereas insulin glargine + short acting analogous insulin (lispro), insulin aspart + neutral protamine aspart (NPA) and insulin lispro + neutral protamin lispro (NPL) groups cosisted of 27, 31 and 26 patients, respectively. Patients were followed up for 6 months. Anthropometric measurements, fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) values of all patients were recorded at 3rd and 6th months.Results: In all groups, we observed statistically significant increase in both weight and body mass index (BMI) (p

Özet

Amaç: Obesite, tip 2 diyabet gelişimini kolaylaştırıcı ve tedavisini zorlaştırıcı bir faktördür. Santral kilo artışı adipoz dokuda artışa, bu da adipokinlerin ve serbest yağ asitlerinin (SYA) artışına ve sonuçta insulin direncine sebep olmaktadır. Oysa ki, iyi glisemik kontrol sağlamak amacıyla oral antidiyabetik (OAD) tedavisinden insulin tedavisine geçilen hastalarda ise kilo artışı gözlenmektedir. Biz bu çalışmamızda farklı insulin tedavilerinin kilo üzerine etkilerini araştırmayı amaçladık.Gereç ve Yöntem: Çalışmaya ilk kez insulin tedavisi uygulanacak 129 diabetes mellituslu (DM) hasta alındı. İnsulin detemir + kısa etkili analog insulin (aspart) uygulanan gurup 18 kişi, insulin glarjin + kısa etkili analog insulin (lispro) uygulanan gurup 27 kişi, insulin aspart + nötral protamin aspart (NPA) uygulanan gurup 31 kişi ve insulin lispro + nötral protamin lispro (NPL) uygulanan gurup 26 kişi idi. Hastalar 6 ay boyunca izlendi. Tüm hastaların 3. ay ve 6. ayda antropometrik ölçümleri, açlık plasma glikoz (APG) ve hemoglobin A1c (HbA1c) değerleri alındı.Bulgular: Tüm guruplarda kiloda ve vücut kitle indeksinde (VKİ) anlamlı artış izlendi (p

🔖

Cite This Article

KEFELİ, A., BAMBUL, N., ÇİFTÇİ, H., OĞUZ, A. (2022). Association of different insulin treatment regimens with weight gain in patients with type 2 diabetes mellitus. Göztepe Tıp Dergisi, Cilt: 24 - Sayı: 4, 183–191. https://ajindex.com/articles/526203

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. The world health report 2006: working together for health. Geneva: World Health Organisation, 2006 http://www.who.int/whr/2006/whr06 en.pdf
  2. Haslam DW, James WP. Obesity. Lancet 2005;366:1197-1209
  3. Roden M, Stingl H, Chandramouli V, et al. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 2000;49(5):701-7
  4. Haak T, Tiengo A, Draeger E, Suntum M, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diab Obes Metab 2005;7:56–64
  5. Raslova K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201
  6. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes care 2006;29(6):1269-74
  7. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):3080-6
  8. Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24(4):631-6
  9. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.Diabetologia 2008;51(3):408-16
  10. Holman RR, Thorne KI, Farmer AJ, et al.Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357(17):1716-30
  11. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28(2):260-5
  12. Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009 Jun 29 (baskıda)
  13. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;2